JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Kodu・Aktsiate loetelu・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

41.06 2.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.87

Max

41.33

Põhinäitajad
By Trading Economics
Sissetulek	-19M -116M
Müük	670K 1M
Kasumimarginaal	-11,216.004
Töötajad	437
EBITDA	-19M -129M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+96.63% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	1.4B 4B
Eelmine avamishind	38.46
Eelmine sulgemishind	41.06

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

30.39 / 33.46 Toetus ja vastupanu

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. okt 2025, 23:52 UTC

Market Talk

Global Equities Roundup: Market Talk

26. okt 2025, 23:52 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

26. okt 2025, 23:46 UTC

Market Talk

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26. okt 2025, 23:41 UTC

Market Talk

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26. okt 2025, 23:34 UTC

Tulu

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26. okt 2025, 23:32 UTC

Tulu

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26. okt 2025, 23:30 UTC

Tulu

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26. okt 2025, 22:29 UTC

Tulu

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26. okt 2025, 22:29 UTC

Tulu

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26. okt 2025, 22:29 UTC

Tulu

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26. okt 2025, 22:29 UTC

Tulu

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26. okt 2025, 22:16 UTC

Tulu

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26. okt 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26. okt 2025, 19:29 UTC

Omandamised, ülevõtmised, äriostud

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26. okt 2025, 06:39 UTC

Tulu

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26. okt 2025, 06:39 UTC

Tulu

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26. okt 2025, 06:39 UTC

Tulu

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24. okt 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. okt 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. okt 2025, 21:07 UTC

Tulu

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. okt 2025, 20:58 UTC

Tulu

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 20:40 UTC

Tulu

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. okt 2025, 20:24 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:23 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:13 UTC

Tulu

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. okt 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. okt 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. okt 2025, 19:33 UTC

Tulu

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

96.63% tõus

12 kuu keskmine prognoos

Keskmine 80.6 USD 96.63%

Kõrge 143 USD

Madal 40 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Crinetics Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.